Abstract
Liver ischemia-reperfusion injury is characterized by cell necrosis and apoptosis and by profound modifications in the extracellular matrix (ECM). During the complex series of events that take place both during ischemia and when normal blood flow is restored (reperfusion), a concerted regulation of release and activation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) mainly by stellate cells, Kupffer cells and inflammatory cells leads first to endothelial cell injury and subsequent infiltration of neutrophils into the wounded area. Later, MMP activation causes degradation of extracellular matrix components of the liver, mainly collagen and fibronectin, altering tissue architecture. The fibrosis that can result after liver injury is also dependent on the imbalance between MMPs and TIMPs and to new collagen deposition. Several experimental models of liver ischemia-reperfusion injury have demonstrated protective effects of MMP inhibitors in terms of cell necrosis, apoptosis and rearrangement of the extracellular matrix. This review summarizes current knowledge of MMP biology, with particular attention to the most recent evidence of novel, non-extracellular matrix MMP substrates involved in inflammation and cell cycle regulation. An overview of MMP and TIMP expression and activation in hepatic ischemia- reperfusion injury is provided. The analysis of such provides a rational basis for MMP inhibition as a viable strategy to prevent liver injury.
Keywords: Matrix metalloproteinase, tissue inhibitor of metalloproteinase, liver, ischemia-reperfusion, oxidative stress, inflammation
Current Pharmaceutical Design
Title: The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Volume: 12 Issue: 23
Author(s): S. Viappiani, M. Sariahmetoglu and R. Schulz
Affiliation:
Keywords: Matrix metalloproteinase, tissue inhibitor of metalloproteinase, liver, ischemia-reperfusion, oxidative stress, inflammation
Abstract: Liver ischemia-reperfusion injury is characterized by cell necrosis and apoptosis and by profound modifications in the extracellular matrix (ECM). During the complex series of events that take place both during ischemia and when normal blood flow is restored (reperfusion), a concerted regulation of release and activation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) mainly by stellate cells, Kupffer cells and inflammatory cells leads first to endothelial cell injury and subsequent infiltration of neutrophils into the wounded area. Later, MMP activation causes degradation of extracellular matrix components of the liver, mainly collagen and fibronectin, altering tissue architecture. The fibrosis that can result after liver injury is also dependent on the imbalance between MMPs and TIMPs and to new collagen deposition. Several experimental models of liver ischemia-reperfusion injury have demonstrated protective effects of MMP inhibitors in terms of cell necrosis, apoptosis and rearrangement of the extracellular matrix. This review summarizes current knowledge of MMP biology, with particular attention to the most recent evidence of novel, non-extracellular matrix MMP substrates involved in inflammation and cell cycle regulation. An overview of MMP and TIMP expression and activation in hepatic ischemia- reperfusion injury is provided. The analysis of such provides a rational basis for MMP inhibition as a viable strategy to prevent liver injury.
Export Options
About this article
Cite this article as:
Viappiani S., Sariahmetoglu M. and Schulz R., The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver, Current Pharmaceutical Design 2006; 12 (23) . https://dx.doi.org/10.2174/138161206777947560
DOI https://dx.doi.org/10.2174/138161206777947560 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Minocycline and Cytoprotection: Shedding New Light on a Shadowy Controversy
Current Drug Delivery Recent Advances in Methods of Puerarin Biotransformation
Mini-Reviews in Medicinal Chemistry Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Atorvastatin Prevents the Neuron Loss in the Hippocampal Dentate Gyrus Region through its Anti-Oxidant and Anti-Apoptotic Activities
CNS & Neurological Disorders - Drug Targets Poly(ADP-ribose)polymerase Inhibition - Where Now?
Current Medicinal Chemistry The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Mechanisms of Liver Injury: An Overview
Current Molecular Medicine Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice
Current Molecular Medicine Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Meet our Editor (Pharmacology)
Current Chinese Science Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments
Current Pharmaceutical Design Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry